| |
|
|
| Registros recuperados : 378 | |
| Registros recuperados : 378 | |
|
|
|
 | Acesso ao texto completo restrito à biblioteca da Embrapa Gado de Leite. Para informações adicionais entre em contato com cnpgl.biblioteca@embrapa.br. |
Registro Completo
|
Biblioteca(s): |
Embrapa Gado de Leite. |
|
Data corrente: |
14/12/2022 |
|
Data da última atualização: |
15/12/2022 |
|
Tipo da produção científica: |
Artigo em Periódico Indexado |
|
Circulação/Nível: |
A - 2 |
|
Autoria: |
OLIVEIRA, G. V. de; MAIA, M. L. P.; LEÃO, F. A. A.; SAD, E. F.; MIOTTO, I. Z.; SILVA, M. R.; RAMOS-E-SILVA, M. |
|
Afiliação: |
GISELE VIANA DE OLIVEIRA, Instituto Mario Penna; MARIA LUISA PELOSO MAIA, Hospital Felício Rocho; FELIPE AUGUSTO AZEVEDO LEÃO, Hospital Felício Rocho; EDUARDO FONSECA SAD, Hospital Felício Rocho; ISADORA ZAGO MIOTTO, Hospital Felício Rocho; MARCIO ROBERTO SILVA, CNPGL; MARCIA RAMOS-E-SILVA, Universidade Federal do Rio de Janeiro. |
|
Título: |
What to expect when AGEP is induced by terbinafine? Case report and critical review of the literature. |
|
Ano de publicação: |
2022 |
|
Fonte/Imprenta: |
Mycoses, v. 65, p. 918-925, 2022. |
|
Idioma: |
Inglês |
|
Conteúdo: |
Background: Acute Generalised Exanthematous Pustulosis (AGEP) is a rash with multiple sterile intraepidermal or subcorneal non-follicular pustules on edematous papules, with a sudden development and rapid evolution, triggered by drugs, vaccination, insect bites, exposure to mercury, and allergens. Objectives and methods: We describe a female patient who developed extensive and abnormally prolonged AGEP following exposure to terbinafine and SARS-CoV vaccine. A detailed review of terbinafine-induced-AGEP cases was performed, with the aim of evaluating if the AGEP criteria would follow a different pattern when the disease is triggered by this drug. A PubMed search helped retrieve all terbinafine-induced AGEP case reports. AGEP-specific Sideroff criteria were analysed in terbinafine-induced cases and compared to other trigger causes. Conclusions: When the AGEP causative drug was terbinafine, a delay in recovery was observed, compared to the existing AGEP criteria when other causes are considered. Terbinafine frequently leads to delayed resolution AGEP probably due to the presence of the drug in the skin for several weeks after exposure, even after discontinuation, and the disease severity may be potentialised by additional factors such as concomitant viral infections or vaccination. |
|
Palavras-Chave: |
Pústula; Pustulose exantemática generalizada aguda; Terbinafina. |
|
Thesagro: |
Doença; Efeito Colateral. |
|
Categoria do assunto: |
H Saúde e Patologia |
|
Marc: |
LEADER 02038naa a2200253 a 4500
001 2149710
005 2022-12-15
008 2022 bl uuuu u00u1 u #d
100 1 $aOLIVEIRA, G. V. de
245 $aWhat to expect when AGEP is induced by terbinafine? Case report and critical review of the literature.$h[electronic resource]
260 $c2022
520 $aBackground: Acute Generalised Exanthematous Pustulosis (AGEP) is a rash with multiple sterile intraepidermal or subcorneal non-follicular pustules on edematous papules, with a sudden development and rapid evolution, triggered by drugs, vaccination, insect bites, exposure to mercury, and allergens. Objectives and methods: We describe a female patient who developed extensive and abnormally prolonged AGEP following exposure to terbinafine and SARS-CoV vaccine. A detailed review of terbinafine-induced-AGEP cases was performed, with the aim of evaluating if the AGEP criteria would follow a different pattern when the disease is triggered by this drug. A PubMed search helped retrieve all terbinafine-induced AGEP case reports. AGEP-specific Sideroff criteria were analysed in terbinafine-induced cases and compared to other trigger causes. Conclusions: When the AGEP causative drug was terbinafine, a delay in recovery was observed, compared to the existing AGEP criteria when other causes are considered. Terbinafine frequently leads to delayed resolution AGEP probably due to the presence of the drug in the skin for several weeks after exposure, even after discontinuation, and the disease severity may be potentialised by additional factors such as concomitant viral infections or vaccination.
650 $aDoença
650 $aEfeito Colateral
653 $aPústula
653 $aPustulose exantemática generalizada aguda
653 $aTerbinafina
700 1 $aMAIA, M. L. P.
700 1 $aLEÃO, F. A. A.
700 1 $aSAD, E. F.
700 1 $aMIOTTO, I. Z.
700 1 $aSILVA, M. R.
700 1 $aRAMOS-E-SILVA, M.
773 $tMycoses$gv. 65, p. 918-925, 2022.
Download
Esconder MarcMostrar Marc Completo |
|
Registro original: |
Embrapa Gado de Leite (CNPGL) |
|
|
Biblioteca |
ID |
Origem |
Tipo/Formato |
Classificação |
Cutter |
Registro |
Volume |
Status |
Fechar
|
| Nenhum registro encontrado para a expressão de busca informada. |
|
|
